{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T13:41:31Z","timestamp":1761745291125,"version":"3.44.0"},"reference-count":11,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jni-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Neuroimmunology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.jneuroim.2020.577308","type":"journal-article","created":{"date-parts":[[2020,6,26]],"date-time":"2020-06-26T13:51:10Z","timestamp":1593179470000},"page":"577308","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Rituximab as an effective therapeutic option in refractory Neuro-Beh\u00e7et syndrome"],"prefix":"10.1016","volume":"346","author":[{"given":"Christian","family":"Garcia-Estrada","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Casallas-Vanegas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Indhira","family":"Zabala-Angeles","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Gomez-Figueroa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ver\u00f3nica","family":"Rivas-Alonso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9","family":"Flores-Rivera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.jneuroim.2020.577308_bb0005","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/j.semarthrit.2014.08.004","article-title":"Tocilizumab for severe refractory neuro-Beh\u00e7et: three cases IL-6 blockade in neuro-Beh\u00e7et","volume":"44","author":"Addimanda","year":"2015","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.jneuroim.2020.577308_bb0010","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.3389\/fimmu.2019.02830","article-title":"Treating the different phenotypes of Beh\u00e7et\u2019s syndrome","volume":"10","author":"Bettiol","year":"2019","journal-title":"Front. Immunol."},{"issue":"7","key":"10.1016\/j.jneuroim.2020.577308_bb0015","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1007\/s10067-011-1726-1","article-title":"Infliximab for patients with neuro-Behcet\u2019s disease: case series and literature review","volume":"30","author":"Borhani-Haghighi","year":"2011","journal-title":"Clin. Rheumatol."},{"key":"10.1016\/j.jneuroim.2020.577308_bb0020","first-page":"826_32","article-title":"Phenotypic characteristics of B cells in Behcet\u2019s disease:increased activity in B cell subsets","volume":"26","author":"Eksioglu-Demiralp","year":"1999","journal-title":"J. Rheumatol."},{"issue":"3","key":"10.1016\/j.jneuroim.2020.577308_bb0025","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1756-185X.2010.01546.x","article-title":"Rituximab in intractable ocular lesions of Behcet\u2019s disease; randomized single-blind control study (pilot study)","volume":"13","author":"Fereydoun","year":"2010","journal-title":"Int. J. Rheum. Dis."},{"key":"10.1016\/j.jneuroim.2020.577308_bb0030","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jocn.2016.03.020","article-title":"Neuro-Beh\u00e7et\u2019s disease presenting with tumour-like lesions and responding to rituximab","volume":"32","author":"Jade","year":"2016","journal-title":"J. Clin. Neurosci."},{"issue":"9","key":"10.1016\/j.jneuroim.2020.577308_bb0035","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1007\/s00415-013-7209-3","article-title":"Diagnosis and management of neuro-Beh\u00e7et\u2019s disease: international consensus recommendations","volume":"261","author":"Kalra","year":"2014","journal-title":"J. Neurol."},{"issue":"4","key":"10.1016\/j.jneuroim.2020.577308_bb0040","first-page":"367","article-title":"Severe neuro-Behcet\u2019s disease treated with a combination of immunosuppressives and a TNF-inhibitor","volume":"41","author":"Korkmaz","year":"2016","journal-title":"Acta Reumatol. Port."},{"key":"10.1016\/j.jneuroim.2020.577308_bb0045","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2014-204366","article-title":"Treatment of myelitis in Beh\u00e7et\u2019s disease with rituximab","volume":"2014","author":"Messina","year":"2014","journal-title":"BMJ Case Rep."},{"issue":"1","key":"10.1016\/j.jneuroim.2020.577308_bb0050","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/rheumatology\/kew366","article-title":"Chronic signs of memory B cell activation in patients with Beh\u00e7et\u2019s disease are partially restored by anti-tumour necrosis factor treatment","volume":"56","author":"van der Houwen","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.jneuroim.2020.577308_bb0055","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/nrrheum.2017.208","article-title":"Beh\u00e7et syndrome: a contemporary view","volume":"14","author":"Yazici","year":"2018","journal-title":"Nat. Rev. Rheumatol."}],"container-title":["Journal of Neuroimmunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572820303076?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165572820303076?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T08:36:36Z","timestamp":1759048596000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165572820303076"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":11,"alternative-id":["S0165572820303076"],"URL":"https:\/\/doi.org\/10.1016\/j.jneuroim.2020.577308","relation":{},"ISSN":["0165-5728"],"issn-type":[{"type":"print","value":"0165-5728"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rituximab as an effective therapeutic option in refractory Neuro-Beh\u00e7et syndrome","name":"articletitle","label":"Article Title"},{"value":"Journal of Neuroimmunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jneuroim.2020.577308","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"577308"}}